Round of more than $6 million, led by Colle Capital Partners with support from Orlando Health Ventures, will fund completion of Sensydia's ongoing ACOUSTIC

由Colle Capital Partners领投、Orlando Health Ventures支持的超600万美元融资轮，将用于资助Sensydia正在进行的ACOUSTIC项目的完成。

‑

-

1 study for the Cardiac Performance System (CPS™) and preparation for commercial launch

1 项针对心脏性能系统（CPS™）的研究及商业化上市准备

LOS ANGELES

洛杉矶

,

，

Oct. 13, 2026

2026年10月13日

/PRNewswire/ -- Sensydia, a clinical-stage medical technology company advancing non-invasive cardiac assessment, today announced an oversubscribed initial closing of more than $6 million in its latest financing, led by Colle Capital Partners with substantial support from Orlando Health Ventures. Proceeds will carry Sensydia's Cardiac Performance System (CPS™) through its ACOUSTIC‑1 study to FDA authorization while supporting commercial launch preparation..

/美通社/ -- 专注于推进无创心脏评估的临床阶段医疗技术公司 Sensydia 今日宣布，其最新一轮融资的首次交割已超额认购，金额超过 600 万美元。本轮融资由 Colle Capital Partners 领投，Orlando Health Ventures 提供大力支持。所筹资金将用于推动 Sensydia 的心脏性能系统（CPS™）完成 ACOUSTIC-1 研究并获得美国食品药品监督管理局（FDA）批准，同时支持商业化发布的准备工作。

Continue Reading

继续阅读

Sensydia’s Cardiac Performance System (CPS™) is designed to give clinicians pulmonary pressure assessments in almost any setting, without the need for invasive catheterization.

Sensydia 的心脏性能系统（CPS™）旨在为临床医生在几乎任何场景下提供肺动脉压评估，而无需进行侵入性导管插入术。

CPS assesses cardiac function by acquiring acoustic and electrical signals and analyzing them using artificial intelligence (AI) algorithms. CPS is designed to provide clinicians in almost any setting with pulmonary pressure assessments, without the need for invasive catheterization, to help identify congestion and guide diagnosis and treatment in heart failure and pulmonary hypertension..

CPS 通过采集声学和电信号，并利用人工智能（AI）算法进行分析，从而评估心脏功能。CPS 旨在为几乎任何医疗环境中的临床医生提供肺动脉压评估，无需进行侵入性导管插入术，以帮助识别充血状况，并指导心力衰竭和肺动脉高压的诊断与治疗。

In July 2026, a new Category III CPT® code, 1036T, took effect for non-invasive hemodynamic assessment built on three key elements: passively acquired acoustic and electrical signals; augmentative algorithmic analysis; and physician review, interpretation, and integration into clinical care — the same approach on which CPS is built..

2026年7月，新的CPT® III类代码1036T生效，用于基于三个关键要素的无创血流动力学评估：被动采集的声学和电信号；辅助性算法分析；以及医师的审查、解读并将其整合到临床护理中——这与构建CPS所采用的方法相同。

'The most important medical technology companies create categories rather than compete in them,' said Bill Hawkins, retired Chairman and CEO of Medtronic and an advisor to Sensydia. 'Sensydia has the makings of one: a new way to bring pressure information to the point of care, and the foundation to scale it.'.

“最重要的医疗技术公司会开创品类，而非在既有品类中竞争。”美敦力前董事长兼首席执行官、Sensydia 顾问比尔·霍金斯表示，“Sensydia 具备成为此类公司的潜质：它提供了一种将压力信息带到诊疗现场的新方法，并拥有实现规模化推广的基础。”

'Cardiologists treating heart failure need the right metric, in the right place, at the right time. We built CPS to give clinicians objective pressure information in the office, where therapy decisions are made,' said Anthony Arnold, CEO of Sensydia. 'With Colle Capital and Orlando Health Ventures behind us, we are focused on bringing CPS to the market rapidly to help patients suffering from heart failure.'.

“治疗心力衰竭的心脏病学家需要在正确的时间、正确的地点获得正确的指标。我们开发CPS旨在为临床医生在诊室中提供客观的压力信息，而诊室正是制定治疗决策的场所，”Sensydia首席执行官安东尼·阿诺德表示。“在Colle Capital和Orlando Health Ventures的支持下，我们致力于迅速将CPS推向市场，以帮助心力衰竭患者。”

'Sensydia built CPS on catheterization data, the clinical gold standard, at a scale few companies attempt,' said Victoria Grace, Founding Partner of Colle Capital Partners. 'That discipline, together with a CPT code already in place, gives us real confidence in this team. We are proud to lead this financing and to back Sensydia.'.

Colle Capital Partners 的创始合伙人维多利亚·格蕾丝表示：“Sensydia 基于作为临床金标准的导管插入数据，以少数公司敢于尝试的规模构建了其 CPS 系统。这种严谨性，加之已有现行的 CPT 代码，使我们对这个团队充满信心。我们很荣幸能领投此次融资并支持 Sensydia。”

About Colle Capital Partners

关于Colle Capital Partners

Colle Capital Partners is a global, opportunistic, early stage technology venture fund. The firm invests at the start of a company's life across AI native businesses, deep technology and infrastructure, backing companies where data compounds into a proprietary moat. Learn more at

Colle Capital Partners 是一家全球性的、机会主义型的早期科技风险投资基金。该基金在企业初创阶段进行投资，聚焦于原生人工智能企业、深度科技及基础设施领域，支持那些能够将数据积累转化为专有护城河的公司。了解更多请访问

colle.vc

colle.vc

.

。

About Orlando Health Ventures

关于奥兰多健康风投

Orlando Health Ventures is advancing healthcare innovation through strategic investments in companies and technologies that are transforming and disrupting the healthcare industry. Through a collaborative effort with our clinicians, team members and leaders, Orlando Health Ventures sources, evaluates and invests in innovative companies that demonstrate potential for high growth opportunity and that align with Orlando Health's mission of delivering high-quality care.

Orlando Health Ventures 通过对正在变革和颠覆医疗健康行业的企业和技术进行战略投资，推动医疗健康创新。通过与我们的临床医生、团队成员和领导者开展协作，Orlando Health Ventures 寻找、评估并投资那些展现出高增长潜力且与 Orlando Health 提供高质量护理的使命相一致的创新企业。

Orlando Health Ventures invests in medtech, biotech and services companies with the potential to help improve patient outcomes and/or improve workflows throughout the health system. Learn more at .

Orlando Health Ventures 投资于具有潜力改善患者预后和/或优化整个医疗系统工作流程的医疗科技、生物科技及服务类公司。了解更多请访问 。

orlandohealth.com/ventures

orlandohealth.com/ventures

.

。

About Sensydia

关于 Sensydia

Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform designed to give clinicians rapid, safe, and accurate assessments of hemodynamic function in the office or clinic, to help them better diagnose and manage heart failure and pulmonary hypertension and improve patient outcomes.

Sensydia 正在开发心脏性能系统（CPS™），这是一个非侵入性平台，旨在为临床医生在办公室或诊所环境中提供快速、安全且准确的血流动力学功能评估，帮助他们更好地诊断和管理心力衰竭及肺动脉高压，从而改善患者预后。

CPS has received FDA Breakthrough Device designation. The company's regulatory history includes FDA 510(k) clearance in 2018 for an algorithm for non-invasive measurement of ejection fraction. Learn more at .

CPS 已获得美国食品药品监督管理局（FDA）的突破性设备认定。该公司的监管历程包括于 2018 年获得 FDA 510(k) 许可，用于一种无创测量射血分数的算法。了解更多详情，请访问。

sensydia.com

sensydia.com

.

。

This release contains forward-looking statements about Sensydia's clinical, regulatory, and commercial plans. Actual results may differ materially, and Sensydia undertakes no obligation to update them.

本新闻稿包含有关 Sensydia 临床、监管和商业计划的前瞻性陈述。实际结果可能存在重大差异，且 Sensydia 不承担更新这些陈述的义务。

Investigational Use Only. CPS is not yet FDA-authorized.

仅限研究使用。CPS 尚未获得美国食品药品监督管理局（FDA）授权。

CPT® is a registered trademark of the American Medical Association.

CPT® 是美国医学会的注册商标。

SOURCE Sensydia

来源 Sensydia

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示